C1s Antibody (Polyclonal)
A goat antiserum raised against human C1s protein.
Product Specifications
| Citations | 8 |
|---|---|
| Clonality |
Polyclonal |
| Immunogen | Highly purified human C1s protein |
| Applications | See citations and technical data sheet for application info. |
| Concentration | > 40 mg/mL |
| Conjugate | Unconjugated |
| Cross Reactivity |
Human, Baboon |
Ordering Information
| Catalog Number | A302 |
|---|---|
| Catalog Number (CE) | N/A |
| Size | 2.0 mL |
| Price (USD) | $200.00 |
| Price (EURO) | 175,00 € |
Contact us
| US Phone | +1 (858) 552 1100 |
|---|---|
| EU Phone | +353 (91) 412 474 |
| US Email | contact-us@quidelortho.com |
| EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
| Description |
A goat antiserum raised against human C1s protein. |
|---|---|
| Size | 2.0 mL |
| Concentration |
> 40 mg/mL |
| Applications | See citations and technical data sheet for application info. |
| Form | Liquid. Whole Antiserum. ≤ 0.1% Sodium Azide |
| Clonality | Polyclonal |
| Immunogen | Highly purified human C1s protein |
| Conjugate | Unconjugated |
| Cross Reactivity | Human, Baboon |
| Isotype | Goat IgG |
| Purity | N/A |
| Source |
Goat |
| Specificity | The Anti-human C1s polyclonal antisera was tested against normal human plasma by double immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodifussion, and quantitative rocket immunoelectrophoresis. The antiserum was determined to be monospecific for C1s at varying concentrations. |
| Storage |
Short term (30 days) 4˚C. Long term at or below –20˚C. |
| Background |
The C1s molecule is a monomeric zymogen protein with a molecular weight of 86 kD. In normal human serum the accepted concentration of C1s is approximately 34 µg/mL. C1s is one of 3 subcomponents that together make the first component of the classical complement pathway, C1. Initiation of the classical complement pathway occurs when C1q binds with IgM or IgG containing antigen-antibody complexes. Upon activation by C1r, the C1s monomer is fragmented into 2 disulfide-linked polypeptide chains, A and B. The enzymatically active site of the C1s molecule is located in the B fragment. With the proteolysis of C1s, C1 becomes active and can then begin to act upon C4 and C2. C1s cleaves C4 into C4a and C4b. C4b then acts as a receptor for C2. Once bound, the C2 becomes a substrate for C1s, which then cleaves C2 into C2a and C2b. C2b remains bound to the C4b creating the C3/C5 convertase of the classical complement pathway. |
Citations
| Title | Year | Applications | Sample Species | Sample | Sample Details |
|---|---|---|---|---|---|
|
Single-cell reconstruction of follicular remodeling in the human adult ovary. |
2019 | IF |
Human |
Ovary Tissue |
Follicular degeneration |
| 2016 | IHC |
Human |
Breast Tissue, Colon Tissue, Lung Tissue, Pancreas Tissue, Skin Tissue |
Malignant cancer |
|
|
Distinct Roles of Classical and Lectin Pathways of Complement in Preeclamptic Placentae. |
2022 | IHC |
Human |
Placenta Tissue |
|
|
Broad Susceptibility of Nucleolar Proteins and Autoantigens to Complement C1 Protease Degradation. |
2017 | WB |
Human |
HeLa Cells |
|
| 2021 | WB |
Human |
Retina Tissue |
||
| 2021 | WB |
Human, Mouse |
Purified protein |
C1q |
|
| 2018 | WB |
Human, Mouse |
Plasma |
Diabetes exosomes |
|
| 2021 | WB |
Mouse |
Eye Tissue |
Retina, Sodium Iodate-Induced Degeneration |